Supportive therapy for low-risk myelodysplastic syndromes

[1] Cazzola M, 2005, HAEMATOLOGICA S2, V90, P306

[2] Cortelezzi A, 2000, Hematol J, V1, P153, DOI 10.1038/sj.thj.6200028

[3] Foley RN, 1998, J AM SOC NEPHROL, V9, P267

[4] Gattermann N, 2005, HEMATOL ONCOL CLI S1, V19, P1

[5] Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (14) : 1456 - 1465

[6] Results of the initial treatment phase of a study of three alternative dosing schedules of Azacitidine (Vidaza(R)) in patients with myelodysplastic syndromes (MDS) [J]. BLOOD, 2007, 110 (11) : 251A - 251A

[7] Malcovati L, 2006, HAEMATOLOGICA, V91, P1588

[8] Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF:: the GFM experience [J]. BLOOD, 2008, 111 (02) : 574 - 582

[9] Rose C, 2007, BLOOD, V110, p80A

[10] Sloand EM, 2004, BLOOD, V104, p401A

[1] Cazzola M, 2005, HAEMATOLOGICA S2, V90, P306

[2] Cortelezzi A, 2000, Hematol J, V1, P153, DOI 10.1038/sj.thj.6200028

[3] Foley RN, 1998, J AM SOC NEPHROL, V9, P267

[4] Gattermann N, 2005, HEMATOL ONCOL CLI S1, V19, P1

[5] Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (14) : 1456 - 1465

[6] Results of the initial treatment phase of a study of three alternative dosing schedules of Azacitidine (Vidaza(R)) in patients with myelodysplastic syndromes (MDS) [J]. BLOOD, 2007, 110 (11) : 251A - 251A

[7] Malcovati L, 2006, HAEMATOLOGICA, V91, P1588

[8] Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF:: the GFM experience [J]. BLOOD, 2008, 111 (02) : 574 - 582

[9] Rose C, 2007, BLOOD, V110, p80A

[10] Sloand EM, 2004, BLOOD, V104, p401A